DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

DIGITAL CONTENT

3 NEWS #PharmaBuzz

media
3 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1229208-44-9, Gs-9973, 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, Entospletinib [inn], Entospletinib (gs-9973), Gs9973

Molecular Formula

C₂₃H₂₁N₇O

Molecular Weight

411.5 g/mol

InChI Key

XSMSNFMDVXXHGJ-UHFFFAOYSA-N

FDA UNII

6I3O3W6O3B

Entospletinib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.

1 2D Structure

Entospletinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine

2.1.2 InChI

InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)

2.1.3 InChI Key

XSMSNFMDVXXHGJ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6

2.2 Other Identifiers

2.2.1 UNII

6I3O3W6O3B

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine

2. Gs-9973

2.3.2 Depositor-Supplied Synonyms

1. 1229208-44-9

2. Gs-9973

3. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine

4. Entospletinib [inn]

5. Entospletinib (gs-9973)

6. Gs9973

7. 6i3o3w6o3b

8. Chembl3265032

9. Syk Inhibitor Gs-9973

10. 6-(1h-indazol-6-yl)-n-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine

11. Imidazo(1,2-a)pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-(4-(4-morpholinyl)phenyl)-

12. 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine

13. 6-(1h-indazol-6-yl)-n-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine

14. Entospletinib [usan:inn]

15. Unii-6i3o3w6o3b

16. 4puz

17. Imidazo[1,2-a]pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-[4-(4-morpholinyl)phenyl]-

18. Gs 9973

19. Gs9973entospletinib

20. Gs-9973; Entospletinib

21. Entospletinib (usan/inn)

22. Entospletinib [usan]

23. Entospletinib [who-dd]

24. Gtpl7889

25. Schembl2483776

26. Dtxsid001317670

27. Hms3653d13

28. Hms3673e05

29. Hms3750e13

30. Amy14224

31. Bcp09582

32. Ex-a1120

33. Bdbm50015448

34. Mfcd28099806

35. Nsc781516

36. Nsc800988

37. S7523

38. Zinc98208742

39. Akos027295322

40. Ccg-264700

41. Db12121

42. Nsc-781516

43. Nsc-800988

44. Sb16830

45. Ncgc00378596-07

46. Ac-30236

47. As-17026

48. Da-36929

49. Hy-15968

50. Ft-0700130

51. Sw220048-1

52. D11209

53. A890877

54. J-690079

55. Q27077193

56. Entospletinib;6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine

57. 6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-(1-methyl-5-{[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino}-6-oxo-1,6-dihydro-3-pyridi Nyl)phenyl]-1(2h)-isoquinolinone

2.4 Create Date

2012-08-20

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₁N₇O
Molecular Weight	411.5 g/mol
XLogP3	3.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	4
Exact Mass	411.18075832 g/mol
Monoisotopic Mass	411.18075832 g/mol
Topological Polar Surface Area	83.4 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	595
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of acute myeloid leukaemia

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Entospletinib manufacturers, exporters & distributors on PharmaCompass

Entospletinib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

4 Drugs in Development

DIGITAL CONTENT

3 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?